FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers

The U.S. Food and Drug Administration (FDA) approved label updates for Bristol Myers Squibb & Co.’s (NYSE:BMY) CAR T cell therapies, Breyanzi (lisocabtagene maraleucel; liso-cel) for large B cell lymphoma (LBCL) and other lymphomas and Abecma (idecabtagene vicleucel; ide-cel) for multiple myeloma.

In the first quarter of 2025, Bristol Myers Squibb reported Abecam sales of $103 million, up 26% year over year, and Breyanzi sales jumped 146% to $204 million.

The company said in a statement on Thursday that these label updates reduce certain patient monitoring requirements and remove the Risk Evaluation and Mitigation Strategy (REMS) programs that had been in place since each product was initially approved.

Also Read: